Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wolfe, G. I.
Right arrow Articles by Barohn, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wolfe, G. I.
Right arrow Articles by Barohn, R. J.
Neurology 1999;52:1487
© 1999 American Academy of Neurology
Brief Communications

Myasthenia gravis activities of daily living profile

G. I. Wolfe, MD, L. Herbelin, R EdT, S. P. Nations, MD, B. Foster, PhD, W. W. Bryan, MD and R. J. Barohn, MD

From the Department of Neurology (Drs. Wolfe, Nations, Bryan, and Barohn, and L. Herbelin) and Academic Computing Services (Dr. Foster), University of Texas Southwestern Medical Center, Dallas, TX.Presented in part at the 50th annual meeting of the American Academy of Neurology; Minneapolis, MN; April 28, 1998.

Address correspondence and reprint requests to Dr. Gil I. Wolfe, Department of Neurology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75235-8897.

The authors have developed an MG activities of daily living (ADL) profile (MG-ADL)—a simple eight-question survey of MG symptoms. In 254 consecutive encounters with established MG patients, the authors compared scores from the MG-ADL to the quantitative MG score (QMG)—a standardized, reliable scale used in clinical trials. The mean MG-ADL score was 4.89 ± 3.63. The mean QMG score was 10.80 ± 5.70. Pearson’s correlation coefficient was 0.583 (p < 0.001). The MG-ADL is an easy-to-administer survey of MG that correlates well with the QMG and can serve as a secondary efficacy measurement in clinical trials.




This article has been cited by other articles:


Home page
 J. Neurol. Neurosurg. PsychiatryHome page
N Matsui, S Nakane, Y Nakagawa, K Kondo, T Mitsui, T Matsumoto, K Arisawa, and R Kaji
Increasing incidence of elderly onset patients with myasthenia gravis in a local area of Japan
J. Neurol. Neurosurg. Psychiatry, October 1, 2009; 80(10): 1168 - 1171.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
The Muscle Study Group
A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis
Neurology, August 5, 2008; 71(6): 394 - 399.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
D. B. Sanders, I. K. Hart, R. Mantegazza, S. S. Shukla, Z. A. Siddiqi, M.H.V. De Baets, A. Melms, M. W. Nicolle, N. Solomons, and D. P. Richman
An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis
Neurology, August 5, 2008; 71(6): 400 - 406.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
J. Cossins, G. Burke, S. Maxwell, H. Spearman, S. Man, J. Kuks, A. Vincent, J. Palace, C. Fuhrer, and D. Beeson
Diverse molecular mechanisms involved in AChR deficiency due to rapsyn mutations
Brain, October 1, 2006; 129(10): 2773 - 2783.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Y. Matsumoto, H. Matsuo, H. Sakuma, I.-K. Park, Y. Tsukada, K. Kohyama, T. Kondo, S. Kotorii, and N. Shibuya
CDR3 Spectratyping Analysis of the TCR Repertoire in Myasthenia Gravis.
J. Immunol., April 15, 2006; 176(8): 5100 - 5107.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
J. Rowin, M. N. Meriggioli, E. Tuzun, S. Leurgans, and P. Christadoss
Etanercept treatment in corticosteroid-dependent myasthenia gravis
Neurology, December 28, 2004; 63(12): 2390 - 2392.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
M. Takamori, M. Motomura, N. Kawaguchi, Y. Nemoto, T. Hattori, H. Yoshikawa, and K. Otsuka
Anti-ryanodine receptor antibodies and FK506 in myasthenia gravis
Neurology, May 25, 2004; 62(10): 1894 - 1896.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
E. Ciafaloni, J.M. Massey, B. Tucker-Lipscomb, and D.B. Sanders
Mycophenolate mofetil for myasthenia gravis: An open-label pilot study
Neurology, January 9, 2001; 56(1): 97 - 99.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
F. Romi, G. O. Skeie, J. A. Aarli, and N. E. Gilhus
The Severity of Myasthenia Gravis Correlates With the Serum Concentration of Titin and Ryanodine Receptor Antibodies
Arch Neurol, November 1, 2000; 57(11): 1596 - 1600.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
A. Jaretzki III, R. J. Barohn, R. M. Ernstoff, H. J. Kaminski, J. C. Keesey, A. S. Penn, and D. B. Sanders
Myasthenia gravis: Recommendations for clinical research standards
Neurology, July 12, 2000; 55(1): 16 - 23.
[Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
A. Jaretzki III, R. J. Barohn, R. M. Ernstoff, H. J. Kaminski, J. C. Keesey, A. S. Penn, and D. B. Sanders
Myasthenia gravis: recommendations for clinical research standards
Ann. Thorac. Surg., July 1, 2000; 70(1): 327 - 334.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by AAN Enterprises, Inc.